GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas.

MLA

Majzner, Robbie G., et al. “GD2-CAR T Cell Therapy for H3K27M-Mutated Diffuse Midline Gliomas.” Nature, vol. 603, no. 7903, Mar. 2022, pp. 934–41. EBSCOhost, https://doi.org/10.1038/s41586-022-04489-4.

APA

Majzner, R. G., Ramakrishna, S., Yeom, K. W., Patel, S., Chinnasamy, H., Schultz, L. M., Richards, R. M., Jiang, L., Barsan, V., Mancusi, R., Geraghty, A. C., Good, Z., Mochizuki, A. Y., Gillespie, S. M., Toland, A. M. S., Mahdi, J., Reschke, A., Nie, E. H., Chau, I. J., … Monje, M. (2022). GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature, 603(7903), 934–941. https://doi.org/10.1038/s41586-022-04489-4

Chicago

Majzner, Robbie G, Sneha Ramakrishna, Kristen W Yeom, Shabnum Patel, Harshini Chinnasamy, Liora M Schultz, Rebecca M Richards, et al. 2022. “GD2-CAR T Cell Therapy for H3K27M-Mutated Diffuse Midline Gliomas.” Nature 603 (7903): 934–41. doi:10.1038/s41586-022-04489-4.